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clinical communities, for up-to-date data on matching and trans-
plant outcome. Only data with the explicit consent of the partici-
pating center have been entered into this database. All data have
been stripped of personal identiﬁers and links to submitting centers
in order to protect patient anonymity. All centers contributing to
this resource are listed on the main page of this project. Currently
updates of the data contained at this site are submitted via the
IHWG database. The HCT database currently contains data on
1551 unrelated donor transplants from 24 centers in 15 countries.
Data cover high resolution HLA typing for patient and donor of
HLA-A, B, C, DRB, DQB, DPB, diagnosis and stage at transplant,
patient and donor age and gender, survival and relapse. Transplant
pairs can be analyzed as deﬁned by the user. Data can be sorted,
viewed and downloaded by HLA allele or allele groups (i.e., HLA-
A*02), level of mismatch, and diagnosis. A special tool allows users
to interactively calculate, display, and download Kaplan Meier
Survival estimates for each user-deﬁned group of transplant pairs.
Download options of the data are available as individual data sets of
donor recipient pairs, as calculated data representing the outcome
of the Kaplan Meier estimate, or as images of Kaplan Meier
Curves. The database has been designed to include additional
genotyping data, e.g. KIR typing, SNPs, or microsatellites for each
donor-recipient pair. As data on additional genes becomes avail-
able, the database will be expanded to allow queries for combina-
tions of different genetic loci.
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THE IMPACT OF AGE AND OBESITY ON PLASMA BUSULFAN LEVELS
Im, E.K.; Cronin, S.; Levine, J.E.; Braun, T.; Yanik, G.; Reynolds, C.;
Uberti, J.P.; Ferrara, J.L.; Hutchinson, R.J. University of Michigan
Blood and Marrow Transplantation Program, Ann Arbor, MI.
IV busulfan is an alternative to oral busulfan in myeloablative
regimens prior to hematopoietic stem cell transplantation
(HSCT). Compared to oral busulfan which has variable bioavail-
ability, IV busulfan assures consistent drug delivery and may be
associated with a lower incidence of regimen-related toxicity. We
were interested in the effect of the type of body weight calculation
used for dosing busulfan on plasma busulfan levels. We investi-
gated the pharmacokinetic data from 58 sequential patients (age
7 m to 67 y) who received IV busulfan. In addition, the pharma-
cokinetic data for 11 patients who were obese or under weight who
received oral busulfan during the study period were also reviewed.
Patients received IV busulfan (0.8 mg/kg), or oral busulfan (1
mg/kg). Patients whose actual weight exceeded 140% of their ideal
body weight were dosed according to ideal [n12] or adjusted
[n29] body weight. The target Css range for all patients was
600–900 ng/ml. Plasma busulfan Css was measured at a single
reference laboratory by gas chromatography and mass spectrome-
try. Based on the pharmacokinetic result, remaining busulfan doses
were adjusted to achieve the desired Css target when averaged over
the 4-day dosing period. There was a signiﬁcant difference in mean
Css values between the IV and oral busulfan groups (727 ng/ml vs
986 ng/ml respectively) (p
0.001); furthermore there was less
variability in the Css for the IV group compared to the oral group
(p0.01). When IV busulfan patients were analyzed, a signiﬁcant
difference was observed among mean Css values of the actual,
ideal, and adjusted ideal body weight groups (658 ng/ml, 707
ng/ml, and 797 ng/ml) (p0.01). Consistent with other studies, we
found an inverse association between the age and busulfan clear-
ance in IV busulfan group (p0.004). In addition, 6/9 patients
between the age of 1 to 10 years had Css below the minimum
target. In this study, patients from 1 to 10 were all dosed by actual
body weight. In conclusion, use of IV busulfan produces a nar-
rower range of Css values. Both age and the choice of body weight
calculation for dosing impacts plasma busulfan levels. Consider-
ation should be given to increase dosing for children
10 years old.
Both adjusted and ideal body weight calculations led to Css values
in the target range. The use of ideal rather than adjusted ideal body
weight for dosing obese patients yielded Css values similar to that
achieved when using actual body weight for non-obese patients.
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BONE MARROW TRANSPLANTATION FOR DYSKERATOSIS CONGENITA:
ANALYSIS OF COMPLICATIONS AND LONG TERM FOLLOW-UP
Bonﬁm, C.M.S.; Bitencourt, M.A.; Funke, V.A.; Setubal, D.C.; Ruiz,
J.; Zanis-Neto, J.; deMedeiros, C.R.; Silva, R.L.F.; Pasquini, R. Bone
Marrow Transplantation Service Hospital de Clinicas UFPR, Curitiba,
PR, Brazil.
Introduction: DC is a rare bone marrow failure syndrome as-
sociated with aplastic anemia in approximately 50% of the cases.
It’s usually inherited in a X-linked manner and the diagnostic triad
includes reticulate hyper pigmentation, nail dystrophy and mucous
leukoplasia. Bone marrow transplantation (BMT) remains the only
potential curative treatment for these pts. Material and Methods:
Between 07/1993 and 07/2001, 5 pts with DC received an HLA
identical sibling BMT in our service. Sex M/F: 4/1. Median age at
BMT: 17 y (8–21).Median previous blood transfusions: 25 UI
(6–50 UI). All but one presented with nail dystrophy, abnormal
skin pigmentation and oral leukoplasia and had severe pancytope-
nia. Preparative regimen: Cyclophosphamide 200 mg/kg. GVHD
prophylaxis: Cyclosporine (csa)  methotrexate. Stem cell source:
bone marrow. TNC infused ranged from 2.2–5.13  108/kg (M:
2.27). Prophylactic antibiotics were given according to common
practice. Results: All pts are alive with a median follow up of 6
years (range: 3.2–11.2 y) and have full donor engraftment. Median
time to reach neutrophils 500/l was 27 days and platelets
20,000/l was 26 days after transplant. Two pts have a lower
platelet count (80,000/l) without any symptoms. Mucositis grade
II occurred in most pts. No pt developed acute or chronic GVHD,
VOD or autoimmune complications. Four pts developed eye com-
plications and two of them had to be submitted to eye surgery
(posterior uveitis and cornea transplantation for bilateral kerato-
conus). Only one pt complained of dry cough and progressive
dyspnea 10 years after transplant. He was evaluated at our BMT
Unit in 07/2004 when he presented with severe dyspnea and
hypoxemia (pO2: 61 mmHg). The chest CT showed diffuse inter-
stitial lesions and spirometry revealed a severe restrictive defect.
Echocardiogram was normal without pulmonary hypertension.
Pulmonary biopsy showed interstitial pulmonary ﬁbrosis with focal
areas of lymphocyte inﬁltrates. He was treated with steroids in
08/2004 and despite the very short follow up there is evidence of
clinical improvement (less fatigue and dyspnea and pO2: 89
mmHg). Conclusions: This preparatory regimen is safe and ef-
fective for the correction of the hematopoietic failure in pts with
DC, followed by a low complication rate. The mucocutaneous
abnormalities remain unchanged. Late pulmonary complications
occurred despite the absence of TBI in the preparative regimen.
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NK CELL ALLOREACTIVITY IS AN IMPORTANT MEDIATOR OF COSTIMU-
LATION-BLOCKADE-RESISTANT REJECTION DURING ALLOGENEIC
TRANSPLANTATION
Kean, L.S.1; Hamby, K.2; Coley, S.2; Lee, E.2; Adams, A.2; Pearson, T.2;
Larsen, C.2 1. Division of Hematology/Oncology/BMT, Department of
Pediatrics, and Department of Surgery, Atlanta, GA; 2. Department of
Surgery, Atlanta, GA.
Introduction: Immunologic tolerance remains an elusive goal of
clinical transplantation. Work in murine systems has demonstrated
that T-cell tolerance can be accomplished by providing T cells
with “signal 1” (alloantigen) while blocking “signal 2” through
costimulation blockade. We have used the costimulation blockade
reagents CTLA4-Ig and anti-CD40L in conjunction with nonmy-
eloablative bone marrow transplant to produce transplantation
tolerance in a fully MHC-mismatched murine system. However,
relatively large bone marrow doses (10  109/kg) must be used.
Costimulation-blockade-resistant rejection occurs when smaller
cell doses are transplanted. In this study, we investigated the
contribution of NK cell alloreactivity to this costimulation-block-
ade-resistant rejection response. Methods: We transplanted in-
creasing doses of Balb/C (NK1.1) bone marrow (0.5-, 2-, 5-, 10-,
and 20  106 cells) into C57BL/6 (NK1.1) mice after treatment
with 20 mg/kg busulfan. Costimulation-blockade with CTLA4-Ig
and anti-CD40L was given in the peritransplant period. Three
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groups were investigated: (1) The effect of NK depletion (with the
depleting antibody, PK136) on engraftment and tolerance was
determined. (2) The effect of NK depletion on engraftment efﬁ-
ciency was tested by transplanting in the presence or absence of
busulfan. (3) We determined if blocking NK signalling with the
anti-adhesion antibody anti-LFA1 could produce effects on en-
graftment similar to those observed with whole-scale NK deple-
tion. Results: (1) Animals with unmanipulated NK cells exhibited
costimulation-blockade resistant rejection when transplanted with
5  106 donor cells. However, NK depletion promoted stable
chimerism even when very low doses of donor marrow (0.5  106)
were infused. The chimeric animals in both the NK replete and
NK-depleted groups were tolerant to their allografts: they exhib-
ited deletion of donor-reactive v5 and v8 CD4 cells and
accepted Balb/C skin grafts. (2) NK depletion had a powerful effect
on engraftment efﬁciency: NK depletion promoted engraftment
even in the absence of busulfan. (3) Blocking NK function with the
anti-LFA1 antibody had the same effect as whole-scale NK deple-
tion with PK136: treated animals became stably chimeric and
tolerant even when very low doses of donor marrow were infused.
Implications: These data highlight the central role that NK cells
play in rejection of allogeneic bone marrow and underscores the
need to control NK alloreactivity during clinical transplantation.
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A MULTI-INSTITUTIONAL STUDY OF EXTRACORPOREAL PHOTOIM-
MUNE THERAPY (ECP) WITH UVADEX FOR THE PREVENTION OF
ACUTE GVHD IN PATIENTS (PTS) UNDERGOING STANDARD MYELOA-
BLATIVE CONDITIONING AND ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHCT)
Abhyankar, S.1; Shaughnessy, P.J.2; Bolwell, B.J.3; van Besien, K.4;
Mistrik, M.5; Grigg, A.6; Dodds, A.7; Prince, H.M.8; Machado, A.9;
Thienel, U.10; Wang, J.10; Foss, F.11; Apperley, J.12, The Photopheresis
Study Group. 1. Kansas City Cancer Center, Kansas City, MO; 2. Texas
Transplant Institute, San Antonio, TX; 3. The Cleveland Clinic Foun-
dation, Cleveland, OH; 4. University of Chicago, Chicago, IL; 5. Klinika
Hematologie a Transfuziologie, Bratislavia, Slovakia (Slovak Republic);
6. Royal Melbourne Hospital, Melbourne, Australia; 7. St. Vincents
Hospital, Sydney, Australia; 8. Peter MacCallum Cancer Institute, East
Melbourne, Australia; 9. Instituto Portugues de Oncologia de Francisco
Gentil, Lisbon, Portugal; 10. Therakos, Exton, PA; 11. New England
Medical Center, Boston, MA; 12. Hammersmith Hospital Imperial
College School of Medicine, London, United Kingdom.
ECP with UVADEX has shown beneﬁt in pts with acute and
chronic GVHD. ECP has shown to reduce the incidence of
GVHD in a reduced intensity conditioning regiment (Foss. BMT.
2004 May). We report preliminary results of the ﬁrst multi-insti-
tutional phase 2 study examining ECP with a standard myeloab-
lative preparative regimen prior to AHCT. ECP was given on 2
consecutive days between D-10 and D-6, followed by cyclophos-
phamide 60 mg/kg/day for 2 days and TBI 1200 cGy over 3 days.
GVHD prophylaxis was Cyclosporine 3–5 mg/kg IV daily begin-
ning D-1, and later switched to PO, adjusted to keep levels 200–
600 ng/ml, and methotrexate 10 mg/m2 on D1, 3, 6, and 11 for pts
who had matched unrelated donors (MUD) or HLA class 1 one-
antigen mismatched related donors (MMRD), or 10 mg/m2 on D1
and 5 mg/m2 on D3, 6, and 11 for pts who had matched related
donors (MRD). Enrollment has been completed and data are
available on 61 of 65 pts. The median age was 39 (20–60) years and
40 (66%) pts were male. Diagnoses included AML/MDS (n20),
ALL (n14), CML (n16), lymphoma (n5), CLL (n3), and
other (n3). 29 pts had MRD, 31 MUD, and 1 MMRD. 28 pts
received bone marrows and 33 patients had PBPC for their trans-
plant. All patients engrafted. Acute GVHD grade 2–4 occurred in
11 (37.9%) pts and grade 3–4 occurred in 2 (7%) pts, who received
MRD transplants (n29); and grade 2–4 in 16 (51.6%) pts and
grade 3–4 in 10 (32.3%) pts, who received MUD transplants
(n31). No aGVHD occurred in 1 pt who received a MMRD
transplant. Mild reversible hypotension related to ECP occurred in
1 pt who was able to continue on study. Chronic GVHD occurred
in 23 of 61 evaluable pts; limited in 15, extensive in 6, and unknown
in 2 pts. There are 43 (70.5%) pts alive at a median follow up of
303 (168–560) days. Actuarial estimates of survival at one year are
83% for pts who received MRD transplants and 63% for pts who
received MUD or MMRD transplants. Causes of death include
relapse (n5), aGVHD (n3), multi-organ-system-failure (n3),
pneumonitis (n4, interstitial/CMV/aspergillus), and 1 each of
infection, neurologic toxicity, and arterial thrombosis. Preliminary
results of this study reveal no adverse affects of ECP on regimen
related toxicity or engraftment after a standard myeloablative
AHCT. The overall survival of pts in this trial is encouraging and
warrants further study.
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HUMAN HERPESVIRUS 6 MANIFESTING AS ENCEPHALITIS IN HEMA-
TOPOIETIC PROGENITOR CELL RECIPIENT AFTER REDUCED INTEN-
SITY ALLOGENEIC TRANSPLANTATION
Ng, N.; Devoe, C.; John, V.; Bayer, R.-L. North Shore-LIJ Health
Systems, Manhasset, NY.
Diagnosis of active Human Herpesvirus 6 (HHV-6) infection in
Hematopoietic Progenitor Cell (HPC) recipients can be difﬁcult
because the virus is ubiquitous and persistent in the human body.
HHV-6 infection usually occurs within 2 to 4 weeks following
transplantation. Infection with HHV-6 can be primary infection or
reactivation. Viral infection can result in clinical symptoms includ-
ing fever, rash, pneumonia, bone marrow suppression, encephalitis
and rejection. There is also a possible correlation between graft
versus host disease and HHV-6. We report a case of a 50 year old
male with a history of refractory Acute Myelogenous Leukemia
(AML). The patient was induced with Etoposide, Ara-C and
Daunorubicin. He relapsed despite consolidation chemotherapy
with HiDAC and Etoposide. He underwent other inductions with-
out lasting response. Bone marrow biopsy after Myelotarg and
HiDAC was hypocellular and he was taken directly to transplan-
tation. The patient underwent a 5/6 HLA mismatched sibling
donor transplant. The preparative regimen included Fludarabine
25 mg/m2/d  5, Melphalan 70 mg/m2/d  2 and ATG. His
GVHD prophylaxis included Cyclosporine and Methotrexate. The
patient engrafted on day 23. Donor chimerism was 100% on day
30. Approximately 3 weeks after transplant, the patient developed
fever, severe myoclonus, mental status changes and amnesia. A
brain MRI showed temporal lobe enhancement. Lumbar puncture
revealed total protein of 58 mg/dL, glucose 80 mg/dL, WBC
1/L, and RBC 1940/L. HHV-6 IgG was 1:320 and IgM was
negative prior to transplantation. The patient required intubation
and blood pressure support. He was treated with IVIG weekly and
Acyclovir initially. Multiplex RT-PCR analysis (Argene, Inc.) of
the CSF was positive for HHV-6. The patient was started on
ganciclovir when the data was obtained; however his status had
improved prior to the change in medications. Follow-up HHV-6
titers 4 weeks after decompensation revealed HHV-6 IgG 1:1280.
The patient developed grade 2–3 GVHD of the gut approximately
day 55. Based on the MRI ﬁndings, the PCR positivity of the spinal
ﬂuid and the amnesia, we suspect that this is active HHV-6 infec-
tion. There have been several cases of encephalitis due to HHV-6
in HPC transplant patients who have presented with amnesia and
who have temporal enhancement on MRI. HHV-6 can be a serious
pathogen in HPC recipients receiving reduced-intensity prepara-
tive regimens.
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PERI-TRANSPLANT IMATINIB ADMINISTRATION RESULTS IN SIGNIFI-
CANT MORTALITY OF RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTS DUE TO IMPAIRED BONE MARROW RECOV-
ERY
Keating, A.R.; McGoldrick, S.; Kochman, A.; Eng, J.M.; Hubbard,
V.M.; van den Brink, M.R.M. Memorial Sloan Kettering Cancer Cen-
ter, New York, NY.
Allogeneic hematopoietic stem cell transplantation (HSCT) is
the only known cure for chronic myeloid leukemia (CML). Ima-
tinib mesylate is able to induce a complete hematologic response in
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